Federal Register of Legislation - Australian Government

Primary content

PB 39 of 2021 Other as made
This instrument amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015) to add, delete and alter listed pharmaceutical items and associated periods and circumstances.
Administered by: Health
Registered 30 Apr 2021
Tabling HistoryDate
Tabled HR11-May-2021
Tabled Senate11-May-2021
To be repealed 12 Aug 2021
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 39 of 2021

 

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 4)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated         28 April      2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA CONNOLLY

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No.4).

(2)          This Instrument may also be cited as PB 39 of 2021.

2          Commencement

This Instrument commences on 1 May 2021.

3          Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                             

                             


Schedule 1       Amendments

[1]             Schedule 1, entry for Mesalazine in the form Tablet 800 mg (enteric coated)

omit from the column headed “Maximum quantity or number of units”: 180                        substitute: 90

[2]             Schedule 1, after entry for Mesalazine in the form Tablet 1.2 g (prolonged release)

insert:

 

Tablet 1.6 g (enteric coated)

20

120

4

 

[3]             Schedule 1, entry for Norethisterone with ethinylestradiol

omit:

 

Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets USP

20

4

2